As a final example, the MMP-9 inhibitor minocycline has been shown in mouse and Drosophila FXS models to correct FXS phenotypes (Bilousova et al., 2008; Siller and Broadie, 2011). This evidence concerns the gene MMP9 and fragile X syndrome.